These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 20532698)

  • 1. Drug mechanisms to help in managing resistant hypertension in obesity.
    Jansen PM; Danser JA; Spiering W; van den Meiracker AH
    Curr Hypertens Rep; 2010 Aug; 12(4):220-5. PubMed ID: 20532698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
    Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME
    Circ Res; 2015 Mar; 116(6):991-1006. PubMed ID: 25767285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Aldosterone in Obesity-Related Hypertension.
    Kawarazaki W; Fujita T
    Am J Hypertens; 2016 Apr; 29(4):415-23. PubMed ID: 26927805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension and the expanding role of aldosterone.
    Mackenzie SM; Connell J
    Curr Hypertens Rep; 2006 Jun; 8(3):255-61. PubMed ID: 17147925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension.
    Contreras F; de la Parte MA; Cabrera J; Ospino N; Israili ZH; Velasco M
    Am J Ther; 2003; 10(6):401-8. PubMed ID: 14624277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reviving the use of aldosterone inhibitors in treating hypertension in obesity.
    Huby AC; Belin De Chantemèle EJ
    Am J Physiol Regul Integr Comp Physiol; 2015 Nov; 309(9):R1065-7. PubMed ID: 26157057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension.
    Gray Z; Tu W; Chertow GM; Bhalla V
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F325-F335. PubMed ID: 33491565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology and treatment of obesity hypertension.
    Wofford MR; Hall JE
    Curr Pharm Des; 2004; 10(29):3621-37. PubMed ID: 15579059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension.
    Katzman PL; Hulthén UL; Hökfelt B
    Acta Med Scand; 1988; 223(2):125-31. PubMed ID: 3279724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M; Fujita T
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone receptor antagonists: current perspectives and therapies.
    Guichard JL; Clark D; Calhoun DA; Ahmed MI
    Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
    Shibata H; Itoh H
    Am J Hypertens; 2012 May; 25(5):514-23. PubMed ID: 22258336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone receptor antagonists: focus on eplerenone.
    Lamb RE; Folstad J
    Prog Cardiovasc Nurs; 2003; 18(1):54-9. PubMed ID: 12624573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.
    Nishiyama A; Hasegawa K; Diah S; Hitomi H
    J Pharmacol Sci; 2010; 113(4):310-4. PubMed ID: 20675957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches in the treatment of hypertension.
    Oparil S; Schmieder RE
    Circ Res; 2015 Mar; 116(6):1074-95. PubMed ID: 25767291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and clinical investigations in patients with low-renin hypertension.
    Mackenzie IS; Brown MJ
    Clin Exp Nephrol; 2009 Feb; 13(1):1-8. PubMed ID: 18704622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a new dawn for selective mineralocorticoid receptor antagonism?
    Luther JM
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
    Pugliese NR; Masi S; Taddei S
    Heart Fail Rev; 2020 Jan; 25(1):31-42. PubMed ID: 31512149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.